Tag Archives: TKI

April, 2018

January, 2018

July, 2017

  • 18 July

    FDA Approves Puma’s Nerlynx for Early Stage HER2-Positive Breast Cancer

    LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) today announced that the U.S. Food and Drug Administration (FDA) has approved NERLYNX™ (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma expects neratinib …

July, 2016

May, 2016

  • 16 May

    FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer

    WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …

April, 2016

December, 2015